URGN Q3 2022 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M+41.8% YoY

Gross Profit

$14M87.5% margin

Operating Income

-$18M-112.4% margin

Net Income

-$26M-160.5% margin

EPS (Diluted)

$-1.13

QoQ Revenue Growth

-3.1%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$128M

Total Liabilities

$192M

Stockholders' Equity

-$63M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$11M	+41.8%
Gross Profit	$14M	$10M	+39.3%
Operating Income	-$18M	-$23M	+22.8%
Net Income	-$26M	-$30M	+14.5%

Revenue Segments

Jelmyto

$16M100%